0001493152-26-009126
SEC filingThe provided document content for GT Biopharma, Inc.'s Q3 2025 10-Q/A filing does not contain the specific financial statements or XBRL data required to report on overall performance, revenue, profit drivers, or forward-looking significance. The document explicitly states that the company qualifies as a smaller reporting company and is not required to provide quantitative and qualitative disclosures about market risk. The primary substantive disclosure relates to internal controls, where management concluded that disclosure controls and procedures were not effective as of September 30, 2025. A material weakness in internal control over financial reporting was identified related to the misclassification of Greenshoe Rights as equity instead of a liability under ASC 480, requiring a restatement of interim financial data for the quarterly periods ended June 30, 2025, and September 30, 2025. No changes in internal controls were reported for the most recent fiscal quarter. A remediation plan involving engaging an accounting consultant for complex transactions was adopted subsequent to September 30, 2025. No financial figures for revenue, profit, or cash flow are provided in the available text.
The provided document content does not include the condensed financial statements (Balance Sheets, Statements of Operations, Statements of Stockholders’ Equity, Statements of Cash Flows) or their notes. Therefore, no key financial results, comparisons to prior periods, or exact figures for performance metrics such as revenue, net income, or earnings per share can be reported. The document's Item 1 section only lists the titles of these financial statements without providing their numerical content. The analysis is limited to the qualitative disclosures present in other sections of the filing.
No revenue data, segment breakdown, geographic mix, or growth drivers are disclosed in the provided document content. The sections containing this information are referenced (Item 1) but their detailed numerical content is not included in the text provided for analysis. Therefore, a revenue analysis cannot be performed based on the available information.
No data on gross margin, operating margin trends, or cost structure changes is available in the provided document content. The financial statements that would contain this information are listed but their figures are not provided. Consequently, an analysis of margins and profitability cannot be conducted.
No data on operating cash flow, free cash flow, debt levels, or liquidity position is available in the provided document content. The condensed statements of cash flows and balance sheets are referenced but their numerical data is not included. Therefore, an analysis of cash flow and the balance sheet cannot be performed.
The document does not contain a management discussion and analysis (MD&A) section, forward-looking statements, management guidance, strategic priorities, or specific risk factors related to business operations or financial outlook. The primary forward-looking element is the disclosure regarding the remediation of the identified material weakness in internal control over financial reporting. The company states that subsequent to September 30, 2025, it adopted additional internal controls wherein an accounting consultant will be engaged to assess the financial statement impact of contemplated complex transactions, such as the issuance of stock purchase rights or other derivative financial instruments, prior to their consummation. No other outlook information is provided.